Support for two subcategories of depression with different vasopressinergic mechanisms in the field of melancholia

Current Psychiatry Reviews

Volumn 5, Issue 2, 2009, Pages 127-136

  Goekoop, Jaap G ^a,b   Wiegant, Victor M ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Rivierduinen   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Animal models; Anxiety; Character; Melancholia; Retardation; Social behavior; Temperament; Vasopressin

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; HYDROCORTISONE; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR;

ANIMAL BEHAVIOR; ANXIETY DISORDER; CHARACTER; COOPERATION; DEPENDENT PERSONALITY DISORDER; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISCRIMINATIVE STIMULUS; FAMILY HISTORY; GLUCOCORTICOID DEXAMETHASONE TEST; HEREDITY; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MELANCHOLIA; MENTAL DEFICIENCY; MENTAL DISEASE; NONHUMAN; PERSONALITY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TEMPERAMENT; VALIDATION PROCESS;

EID: 70350025035     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340009788167356     Document Type: Review

References (65)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press: Washington DC.
2. van Praag HM. Diagnosis, the rate-limiting factor of biological depression research. Neuropsychobiology 1993; 28: 197-206.
3. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970; 126: 983-7.
4. Goekoop JG, Hoeksema T, Knoppert-Van der Klein EA, et al. Multidimensional ordering of psychopathology. A factor-analytic study using the comprehensive psychopathological rating scale. Acta Psychiatr Scand 1992; 86: 306-12.
5. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993; 50: 975-990.
6. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993; 14: 76-122.
7. Carney MW, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of ECT. Br J Psychiatry 1965; 111: 659-74.
8. Zimmerman M, Pfohl B, Stangl D, Coryell W. An American validation study of the Newcastle diagnostic scale. I. Relationship with the dexamethasone suppression test. Br J Psychiatry 1986;149: 627-630.
9. Duggan CF, Lee AS, Murray RM. Do different subtypes of hospitalized depressives have different long-term outcomes? Arch Gen Psychiatry 1991; 48: 308-12.
10. Jaspers K. (1963) General Psychopathology. Manchester University Press: Manchester.
11. Troisfontaines B, Bobon D [Scales, factor analysis and subscales of the French-language AMDP system]. Acta Psychiatr Belg 1987; 87: 23-60.
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
13. Goekoop JG, de Beurs E, Zitman FG. Four-dimensional structure underlying scales for depression anxiety and retardation: emergence of trapped anger and scale improvements. Compr Psychiatry 2007; 48: 192-8.
14. Svrakic DM, Whitehead C, Przybeck TR, Cloninger CR. Differential diagnosis of personality disorders by the seven-factor model of temperament and character. Arch Gen Psychiatry 1993; 50: 991-99.
15. De Fruyt F, De Clercq BJ, van de WL, Van Heeringen K. The validity of Cloninger's psychobiological model versus the five-factor model to predict DSM-IV personality disorders in a heterogeneous psychiatric sample: domain facet and residualized facet descriptions. J Pers 2006; 74: 479-510.
16. Widiger TA, Trull TJ. Assessment of the five-factor model of personality. J Pers Assess 1997; 68: 228-50.
17. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press: Washington, DC.
18. Ando J, Suzuki A, Yamagata S, et al. Genetic and environmental structure of Cloninger's temperament and character dimensions. J Personal Disord 2004;18: 379-93.
19. Gillespie N, Cloninger C, Heath A, Martin N. The genetic and environmental relationship between Cloninger's dimensions of temperament and character. Pers Individ Dif 2003; 35: 1931-46.
20. Gutknecht L, Jacob C, Strobel A, et al. Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation. Int J Neuropsychopharmacol 2007;10: 309-20.
21. Serretti A, Mandelli L, Lorenzi C, et al. Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms. Neuropsychobiology 2006; 53: 9-16
22. Gerra G, Zaimovic A, Timpano M, Zambelli U, Delsignore R, Brambilla F. Neuroendocrine correlates of temperamental traits in humans. Psychoneuroendocrinology 2000; 25: 479-96
23. Bell CJ, Nicholson H, Mulder RT, Luty SE, Joyce PR. Plasma oxytocin levels in depression and their correlation with the temperament dimension of reward dependence. J Psychopharmacol 2006; 20: 656-60.
24. Tse WS, Bond AJ. The Application of the temperament and character inventory (TCI) in predicting general social adaptation and specific social behaviors in a dyadic interaction. J Appl Soc Psychol 2005; 35: 1571-86.
25. Kendler KS, Gatz M, Gardner CO, Pedersen NL. Personality and major depression: a Swedish longitudinal, population-based twin study. Arch Gen Psychiatry 2006; 63: 1113-20.
26. Dinan TG, Scott LV. Anatomy of melancholia: focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin. J Anat 2005; 207: 259-64.
27. Van Londen L, Goekoop JG, van Kempen GM, et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997; 17: 284-92.
28. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997;154: 1497-503.
29. Von Bardeleben U, Holsboer F, Stalla GK, Muller OA. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 1985; 37: 1613-18.
30. Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, Grossman AB. Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J Clin Endocrinol Metab 1999; 84: 2238-40.
31. Mlynarik M, Zelena D, Bagdy G, Makara GB, Jezova D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav 2007; 51: 395-405.
32. Landgraf R, Kessler MS, Bunck M, et al. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 2007a; 31: 89-102.
33. Keck ME, Wigger A, Welt T, et al. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 2002; 26: 94-105
34. Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress 2004; 7: 75-83.
35. Bielsky IF, Hu SB, Ren X, Terwilliger EF, Young LJ. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 2005; 47: 503-13.
36. Cooper MA, Karom M, Huhman KL, Albers HE. Repeated agonistic encounters in hamsters modulate AVP V1a receptor binding. Horm Behav 2005; 48: 545-51.
37. Lim MM, Wang Z, Olazabal DE, Ren X, Terwilliger EF, Young LJ. Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene. Nature 2004; 429: 754-57.
38. Kozorovitskiy Y, Hughes M, Lee K, Gould E. Fatherhood affects dendritic spines and vasopressin V1a receptors in the primate prefrontal cortex. Nat Neurosci 2006; 9: 1094-5.
39. Griebel G, Simiand J, Serradeil-Le Gal C, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 2002; 99: 6370-5.
40. Griebel G, Stemmelin J, Gal CS, Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 2005; 11: 1549-59.
41. Salome N, Stemmelin J, Cohen C, Griebel G. Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats. Psychopharmacology (Berl) 2006a; 187: 237-44.
42. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994; 60: 436-44.
43. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996; 53: 137-43.
44. Van Londen L, Kerkhof GA, van den BF, et al. Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998; 43: 196-204.
45. Watson S, Gallagher P, Ferrier IN, Young AH. Post-dexamethasone arginine vasopressin levels in patients with severe mood disorders. J Psychiatr Res 2006; 40: 353-9.
46. Dinan TG, O'Brien S, Lavelle E, Scott LV. Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med 2004; 34: 169-72.
47. Inder WJ, Donald RA, Prickett TC, et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry 1997; 42: 744-7.
48. Brunner J, Keck ME, Landgraf R, Uhr M, Namendorf C, Bronisch T. Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results. Eur Neuropsychopharmacol 2002; 12: 489-94.
49. De Winter RF, Zwinderman KH, Goekoop JG. Anxious-retarded depression: relation to family history of depression. Psychiatry Res 2004; 127: 111-9.
50. Goekoop JG, de Winter RP, de Rijk R, Zwinderman KH, Frankhuijzen-Sierevogel A, Wiegant VM. Depression with above-normal plasma vasopressin: validation by relations with family history of depression and mixed anxiety and retardation. Psychiatry Res 2006;141: 201-11.
51. De Winter RF, Wolterbeek R, Spinhoven P, Zitman FG, Goekoop JG. Character and temperament in major depressive disorder and a highly anxious-retarded subtype derived from melancholia. Compr Psychiatry 2007; 48: 426-35.
52. De Winter RF, Zitman FG, van Houwelingen JC, Wolterbeek R, Goekoop JG. Anxious-retarded depression: relation to two-year outcome of major depressive disorder. J Affect Disord 2006; 90: 77-81.
53. Parker G, Wilhelm K, Mitchell P, Gladstone G. Predictors of 1-year outcome in depression. Aust N Z J Psychiatry 2000; 34: 56-6454.
54. De Winter RF, van Hemert AM, DeRijk RH, et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003; 28: 140-7.
55. Goekoop JG, de Winter RFP, Wolterbeek R, Spinhoven Ph, Zitman FG, Wiegant VM. Reduced cooperativeness and reward-dependence in depression with above-normal plasma vasopressin concentration. J Psychopharmacol 2008; PMID: 18583437.
56. Dempster EL, Burcescu I, Wigg K, et al. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch Gen Psychiatry 2007; 64: 1189-95.
57. Van Londen, L. Vasopressin in major depression. (2003). Leiden University Thesis/Dissertation.
58. Kovacs KJ, Foldes A, Sawchenko PE. Glucocorticoid negative feedback selectively targets vasopressin transcription in parvocellular neurosecretory neurons. J Neurosci 2000; 20: 3843-52.
59. Momeni N, Nordstrom B, Avarsaji H, Joghataei MT, Sivberg B, Persson BL. (2007) High plasma levels of arginine vasopressin (AVP) in children with autism spectrum disorders. In: Neumann ID, Bosch O, Landgraf R (eds) VIIth World Congress on Neurohypophysial Hormones, Regensburg, p 108.
60. Kloet CS de, Vermetten E, Geuze E, Wiegant VM, Westenberg HG. Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder. J Psychiatr Res 2008; 42:192-8.
61. Schmidt ED, Binnenkade R, Janszen AW, Tilders FJ. Short stressor induced long lasting increases of vasopressin stores in hypothalamic corticotropin-releasing hormone (CRH) neurons in adult rats. J Neuroendocrinol 1996; 8: 703-12.
62. Rinne T, de Kloet ER, Wouters L, Goekoop JG, DeRijk RH, van den Brink W. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 2002; 52:1102-12.
63. van Praag HM. Anxiety and increased aggression as pacemakers of depression. Acta Psychiatr Scand Suppl 1998; 393: 81-8.
64. Hamer DH, Greenberg BD, Sabol SZ, Murphy DL. Role of the serotonin transporter gene in temperament and character. J Pers Disord 1999; 13: 312-27.
65. Lyons-Ruth K, Holmes BM, Sasvary-Szekely M, Ronai Z, Nemoda Z, Pauls D. Serotonin transporter polymorphism and borderline or antisocial traits among low-income yound adults. Psychiatr Genet 2007; 17: 339-43.